A Phase 2 interventional study of rituximab [MabThera/Rituxan] and First line chemotherapy in Mantle Cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 7 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies testing rituximab in Lymphoma, Mantle-Cell — 12 open to participants now, 30 under way, 3 of them phase 3. Rituximab · Lymphoma, Mantle-Cell.
Among the 157 studies testing rituximab in Lymphoma, Mantle-Cell, this one is the 59th largest by enrollment of the 153 interventional ones that give a count, is one of 6 that started in 2007, is one of 92 in phase 2, and was the 61st registered.
1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →12 of the 157 studies testing rituximab in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Portugal, Spain
Ages 18+
Christine Ryan · Sites in United States
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 117 · Phase 3 14 · Phase 4 1
First in 1997; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 37 across 1,003 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 37 across the 153 interventional studies. Of the 115 that completed or were terminated, 60 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 157 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 1 study filed under Lymphoma, Mantle-Cell — fewer than ten, so there is no comparison to draw.
9 of the studies testing rituximab in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03267433Phase 3ECOG-ACRIN Cancer Research GroupRituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | 2027-01-31 |
| NCT06496308Phase 3Ruijin HospitalBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | 2027-07-10 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06522386M.D. Anderson Cancer CenterGATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | 2027-02-28 |
| NCT03710772M.D. Anderson Cancer CenterIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-03-22 |
Add all 9 to your calendar (.ics) → With an account.
Among the 157 studies testing rituximab in Lymphoma, Mantle-Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the benefit of adding MabThera to standard induction chemotherapy in patients with newly diagnosed mantle cell lymphoma. The safety and tolerability of a MabThera-containing first line regimen will also be assessed. All patients will receive MabThera (375mg/m2 iv) every 3 weeks for 8 cycles, in combination with standard chemotherapy. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: First line chemotherapy
Drug page: Rituximab
375mg/m2 iv every 3 weeks
As prescribed
Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR)
CR was defined by: a) disappearance of clinical/radiographic evidence of disease, disease-related symptoms, and biochemical abnormalities; b) decrease in lymph nodes (LNs) greater than (\>) 1.5 centimeters (cm) in greatest transverse diameter (GTD) to less than (\<) 1.5 cm, a decrease in LNs 1.1 - 1.5 cm to 1 cm or 75 percent (%) decrease in sum of the products of GTD (SPD); c) non-palpable spleen, decreased size of enlarged organs, and disappearance of nodules; and d) disappearance of bone marrow (BM) infiltrate. CR(u) was defined as fulfilling a) and c), above, with greater than or equal to (≥) 1 of the following: a) \> 75% decrease in SPD of LNs \> 1.5 cm, and \> 75% decrease in SPD of previously confluent LNs; b) indeterminate BM, or c) confirmed CR. PR was defined by: a) 50% decrease in SPD of the 6 largest LNs; b) no increase in LNs, liver, or spleen size; c) ≥ 50% decrease in splenic and hepatic nodule SPDs; d) no measurable disease in other organs; and e) no new sites of disease.
Time frame: Screening, Baseline (BL), every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)
Progression Free Survival (PFS)
PFS was defined as the median time, in months, from the date of study entry to disease progression, death due to mantle cell lymphoma, or last contact. Progressive disease (PD) was defined by: a) 50% increase from nadir in the SPD of any previously identified abnormal LN, or b) appearance of any new lesion during or at the end of treatment. The 95% confidence interval (CI) was estimated using Kaplan-Meier methodology.
Time frame: Screening, BL, every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)
Event Free Survival (EFS)
EFS was defined as the median time, in months, from the date of study entry disease progression, relapse, secondary malignancy, death or last contact. Relapse was defined by: a) appearance of any new lesion or a ≥ 50% increase in size of previously involved sites, or b) ≥ 50% increase in GTD of any previously identified LN \>1 cm in short axis or in the SPD of more than one LN. The 95% CI was estimated using Kaplan-Meier methodology.
Time frame: Screening, BL, every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)
| Milestone | Rituximab Plus (+) Chemotherapy |
|---|---|
| Started | 48 |
| Completed | 32 |
| Not completed | 16 |
| Withdrew: Physician decision | 9 |
| Withdrew: Adverse event | 3 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Death | 3 |
| Milestone | Rituximab Plus (+) Chemotherapy |
|---|---|
| Started | 32 |
| Completed | 15 |
| Not completed | 17 |
| Withdrew: Death | 5 |
| Withdrew: Physician decision | 9 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Protocol violation | 1 |
CR was defined by: a) disappearance of clinical/radiographic evidence of disease, disease-related symptoms, and biochemical abnormalities; b) decrease in lymph nodes (LNs) greater than (\>) 1.5 centimeters (cm) in greatest transverse diameter (GTD) to less than (\<) 1.5 cm, a decrease in LNs 1.1 - 1.5 cm to 1 cm or 75 percent (%) decrease in sum of the products of GTD (SPD); c) non-palpable spleen, decreased size of enlarged organs, and disappearance of nodules; and d) disappearance of bone marrow (BM) infiltrate. CR(u) was defined as fulfilling a) and c), above, with greater than or equal to (≥) 1 of the following: a) \> 75% decrease in SPD of LNs \> 1.5 cm, and \> 75% decrease in SPD of previously confluent LNs; b) indeterminate BM, or c) confirmed CR. PR was defined by: a) 50% decrease in SPD of the 6 largest LNs; b) no increase in LNs, liver, or spleen size; c) ≥ 50% decrease in splenic and hepatic nodule SPDs; d) no measurable disease in other organs; and e) no new sites of disease.
| participants | Rituximab + Chemotherapy |
|---|---|
| CR | 19 |
| PR | 8 |
PFS was defined as the median time, in months, from the date of study entry to disease progression, death due to mantle cell lymphoma, or last contact. Progressive disease (PD) was defined by: a) 50% increase from nadir in the SPD of any previously identified abnormal LN, or b) appearance of any new lesion during or at the end of treatment. The 95% confidence interval (CI) was estimated using Kaplan-Meier methodology.
| months | Rituximab + Chemotherapy |
|---|---|
| Progression Free Survival (PFS) | 30.456 (19.011 to 41.901) |
EFS was defined as the median time, in months, from the date of study entry disease progression, relapse, secondary malignancy, death or last contact. Relapse was defined by: a) appearance of any new lesion or a ≥ 50% increase in size of previously involved sites, or b) ≥ 50% increase in GTD of any previously identified LN \>1 cm in short axis or in the SPD of more than one LN. The 95% CI was estimated using Kaplan-Meier methodology.
| months | Rituximab + Chemotherapy |
|---|---|
| Event Free Survival (EFS) | 40.049 (33.296 to 46.802) |
Collected over Adverse events (AEs) were recorded throughout the study up to 3 months after the last study drug administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Chemotherapy | — | 25/48 (52.1%) | 23/48 (47.9%) |
| Event | Rituximab + Chemotherapy |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/48 |
| PancytopeniaBlood and lymphatic system disorders | 4/48 |
| PneumoniaInfections and infestations | 4/48 |
| AgranulocytosisBlood and lymphatic system disorders | 4/48 |
| PyrexiaGeneral disorders | 3/48 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/48 |
| SepsisInfections and infestations | 2/48 |
| Deep vein thrombosisVascular disorders | 2/48 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/48 |
| Event | Rituximab + Chemotherapy |
|---|---|
| AgranulocytosisBlood and lymphatic system disorders | 5/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/48 |
| ChillsGeneral disorders | 4/48 |
| PyrexiaGeneral disorders | 3/48 |
| PancytopeniaBlood and lymphatic system disorders | 2/48 |
| DiarrhoeaGastrointestinal disorders | 2/48 |
| PneumoniaInfections and infestations | 2/48 |
| Diarrhoea infectiousGastrointestinal disorders | 1/48 |
| BacteremiaBlood and lymphatic system disorders | 1/48 |
| Herpes zosterInfections and infestations | 1/48 |
Intent-to-treat (ITT) population: all randomized participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | Rituximab + Chemotherapy |
|---|---|
| Median | 70.20 (44.46 to 82.31) |
| Sex: Female, Male(Participants) | Rituximab + Chemotherapy |
|---|---|
| Female | 16 |
| Male | 32 |
Ran from Jun 2007 to primary completion in May 2011, 46 months.
Results were first posted in Nov 2014, 3 years 6 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 46 months is close to that.
Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab